236 related articles for article (PubMed ID: 33580974)
21. Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia.
Breese EH; Krupski C; Nelson AS; Perentesis JP; Phillips CL
J Pediatr Hematol Oncol; 2021 May; 43(4):152-154. PubMed ID: 32496443
[TBL] [Abstract][Full Text] [Related]
22. Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome.
Tu S; Huang R; Guo Z; Deng L; Song C; Zhou X; Yue C; Zhang L; He Y; Yang J; Liang Z; Du J; Cao P; Li Y; Chang LJ; Li Y
Am J Hematol; 2019 Dec; 94(12):E322-E325. PubMed ID: 31489688
[No Abstract] [Full Text] [Related]
23. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
24. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
25. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
26. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
27. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
28. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
29. Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.
Hu L; Charwudzi A; Li Q; Zhu W; Tao Q; Xiong S; Zhai Z
Ann Hematol; 2021 Apr; 100(4):1003-1012. PubMed ID: 33587155
[TBL] [Abstract][Full Text] [Related]
30. CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
Wei G; Hu Y; Pu C; Yu J; Luo Y; Shi J; Cui Q; Wu W; Wang J; Xiao L; Wu Z; Huang H
Ann Hematol; 2018 May; 97(5):781-789. PubMed ID: 29417201
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with the clinical outcome of patients with relapsed/refractory CD19
Ortiz-Maldonado V; Rives S; Español-Rego M; Alonso-Saladrigues A; Montoro M; Magnano L; Giné E; Pascal M; Díaz-Beyá M; Castella M; Català A; Faura A; Rodríguez-Lobato LG; Oliver-Caldes A; Martínez-Roca A; Rovira M; González-Navarro EA; Ortega JR; Cid J; Lozano M; Garcia-Rey E; Fernández S; Castro P; Jordan I; Villamor N; Aymerich M; Torrebadell M; Deyà À; Fernández de Larrea C; Benitez-Ribas D; Trias E; Varea S; Calvo G; Esteve J; Urbano-Ispizua A; Juan M; Delgado J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907029
[No Abstract] [Full Text] [Related]
32. Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
Geyer MB; Manjunath SH; Evans AG; Park JH; Davila ML; Cutler CS; Wang X; Wang Y; Senechal B; Rivière I; Sadelain M; Liesveld JL; Brentjens RJ
Leuk Lymphoma; 2018 Jul; 59(7):1717-1721. PubMed ID: 29043880
[No Abstract] [Full Text] [Related]
33. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
34. The what, when and how of CAR T cell therapy for ALL.
Frey N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):275-281. PubMed ID: 29050700
[TBL] [Abstract][Full Text] [Related]
35. An owner's manual for CD19 "CAR"-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia.
Laetsch TW; Yanik GA; Boyer MW; Rheingold SR
Blood Rev; 2021 Nov; 50():100848. PubMed ID: 33994222
[TBL] [Abstract][Full Text] [Related]
36. Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy.
Wang K; Zhao Y; Wang X; Wang B; Qin M; Zhu G; Wu H; Liu Z; Zheng X; Zheng H; Chen Z
Front Immunol; 2020; 11():581116. PubMed ID: 33424835
[TBL] [Abstract][Full Text] [Related]
37. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
Nagle K; Tafuto B; Palladino Kim L; Parrott JS
Med Oncol; 2018 Sep; 35(11):144. PubMed ID: 30206753
[TBL] [Abstract][Full Text] [Related]
38. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
Zhang X; Li JJ; Lu PH
Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
[TBL] [Abstract][Full Text] [Related]
39. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
[TBL] [Abstract][Full Text] [Related]
40. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Maude SL; Laetsch TW; Buechner J; Rives S; Boyer M; Bittencourt H; Bader P; Verneris MR; Stefanski HE; Myers GD; Qayed M; De Moerloose B; Hiramatsu H; Schlis K; Davis KL; Martin PL; Nemecek ER; Yanik GA; Peters C; Baruchel A; Boissel N; Mechinaud F; Balduzzi A; Krueger J; June CH; Levine BL; Wood P; Taran T; Leung M; Mueller KT; Zhang Y; Sen K; Lebwohl D; Pulsipher MA; Grupp SA
N Engl J Med; 2018 Feb; 378(5):439-448. PubMed ID: 29385370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
